Steve Jackson (scientist)
| Stephen Jackson | |
|---|---|
_Jackson_-_26837860422.jpg) |
|
| Born | Stephen Philip Jackson 17 July 1962 Nottingham, England |
| Nationality | British |
| Fields |
Cancer DNA repair Cell biology Molecular biology |
| Institutions |
Gurdon Institute University of Cambridge University of California, Berkeley University of Edinburgh |
| Alma mater |
University of Leeds (BSc) Imperial College London (PhD) University of Edinburgh (PhD) |
| Thesis | Cloning and characterisation of the RNA8 gene of Saccharomyces cerevisiae (1987) |
| Doctoral advisor | Jean Beggs |
| Known for | Understanding cellular responses to DNA damage and their relevance to cancer |
| Notable awards |
EMBO member (1997) Fellow of the Royal Society (2008) FMedSci (2001) Buchanan Medal (2011) King Faisal International Prize (2016) Dr. A.H. Heineken Prize for Medicine (2016) |
|
Website www www2 |
|
Stephen Philip Jackson, FRS, FMedSci, (born 17 July 1962) is the Frederick James Quick Professor of Biology. He is a Senior Group Leader and Head of Cancer Research UK Laboratories at the Gurdon Institute. He is also part-time Chief Scientific Officer for MISSION Therapeutics Ltd.
Professor Jackson was educated at the University of Leeds, graduating with a Bachelor of Science degree in Biochemistry in 1983. He then carried out his PhD research working with Jean Beggs on yeast RNA splicing at Imperial College London and Edinburgh University, earning his PhD in 1987.
Following his PhD, Jackson carried out postdoctoral research with Robert Tjian at the University of California, Berkeley, where he developed an interest in the regulation of transcription. He returned to the UK in 1991 as a Junior Group Leader at the then Wellcome-CRC Institute, now the Gurdon Institute.
In 1997 Jackson founded KuDOS Pharmaceuticals with the aim of translating knowledge of DNA damage response pathways into new treatments for cancer. KuDOS developed into a fully integrated drug-discovery and drug-development company and was acquired by AstraZeneca in 2005.
In 2011 Jackson founded MISSION Therapeutics a firm to develop drugs to improve the management of life-threatening diseases, particularly cancer.
Jackson has received various prizes, including the Biochemical Society GlaxoSmithKline Award (2008), the BBSRC Innovator of the Year Award (2009), the Royal Society Buchanan Medal (2011), the latter in recognition of his "outstanding contributions to understanding DNA repair and DNA damage response signalling pathways", and the Gagna A. & Ch. Van Heck Prize (2015) for "his cardinal contributions related to cellular events that detect, signal the presence of and repair DNA damages". Jackson is the co-winner of the King Faisal International Prize for Science 2016, in recognition of his "outstanding contribution to defining the link between the basic mechanism of genomic DNA instability and its relationship to cancer. Specifically, he unraveled the salient components of the pathway involved in DNA repair. He is also credited with an innovative approach to bring his findings into tangible therapeutic products to treat cancer". He was elected a member of the European Molecular Biology Organization (EMBO) in 1997, a Fellow of the Academy of Medical Sciences in 2001 and a Fellow of the Royal Society in 2008. In 2016 Jackson won the Dr A.H. Heineken Prize for Medicine for his "fundamental research into DNA repair in human cells and for the successful application of knowledge of that process in the development of new cancer drugs". In 2017 he was awarded the Genome Stability Network medal for his contributions to the field of genome stability and particularly for the realisation of the therapeutic potential of targeting the DDR.
...
Wikipedia